Quantcast

Systemic Sclerosis Pipeline Insights, 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Systemic Sclerosis Pipeline Insights, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Systemic Sclerosis Pipeline Insights, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Sclerosis market.

A detailed picture of the Systemic Sclerosis pipeline landscape is provided, which includes the disease overview and Systemic Sclerosis treatment guidelines. The assessment part of the report embraces in-depth Systemic Sclerosis commercial assessment and clinical assessment of the Systemic Sclerosis pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Systemic Sclerosis with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Systemic Sclerosis treatment.
  • Systemic Sclerosis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Systemic Sclerosis market.

Scope of the Report

  • The Systemic Sclerosis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Systemic Sclerosis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Systemic Sclerosis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
  • Detailed Systemic Sclerosis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Systemic Sclerosis.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Systemic Sclerosis.
  • In the coming years, the Systemic Sclerosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Systemic Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Systemic Sclerosis treatment market. Several potential therapies for Systemic Sclerosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Systemic Sclerosis market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Systemic Sclerosis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions Answered

  • What are the current options for Systemic Sclerosis treatment?
  • How many companies are developing therapies for the treatment of Systemic Sclerosis?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Systemic Sclerosis?
  • How many Systemic Sclerosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Systemic Sclerosis?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Systemic Sclerosis market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Systemic Sclerosis?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Systemic Sclerosis therapies?
  • What are the clinical studies going on for Systemic Sclerosis and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Systemic Sclerosis?
  • How many patents are granted and pending for the emerging therapies for the treatment of Systemic Sclerosis?

Companies Mentioned

  • Emerald Health Pharmaceuticals Inc.
  • Beijing Continent Pharmaceutical Co, Ltd.
  • Shanghai Genomics, Inc.
  • GNI-EPS Pharmaceuticals, Inc. (GNI Group)
  • CSL Behring
  • Galapagos N.V.
  • Corbus Pharmaceuticals Inc.
  • Kyowa Kirin Co. Ltd.
  • Formation Biologics
  • Fibrocell Technologies, Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a8e33l

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.